Relevant Events up to December 31st, 2019

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.

2019

Grifols presents its latest Alzheimer's clinical trial data Payment details of the interim dividend on account of 2019 earnings Grifols completes its debt-refinancing in record time and with strong acceptance for EUR 5,800 million Grifols and Shanghai RAAS obtain authorization for their strategic alliance in China Grifols approves the payment of an interim dividend on account of 2019 Grifols increases its revenues by 14.5% to EUR 3,738 million Grifols to initiate secured debt-refinancing for an amount of EUR 5,300 million Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan Grifols presents additional encouraging Alzheimer's trial results Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies Information on the resolutions approved at the General Meeting of Shareholders on May 24, 2019 Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance Grifols expands its plasma collection network by acquiring IBBI Notice of Annual General Shareholders' Meeting 2019 Grifols presents additional results of its AMBAR clinical trial to treat Alzheimer´s Grifols enters a strategic alliance with Shanghai RAAS in China

2018

Grifols monetizes its recent strategic acquisitions and reinforces its financial structure to support growth opportunities Change of category of Mr. Ramón Riera Roca Payment details of the interim dividend on account of 2018 earnings Grifols enters talks with Shanghai RAAS regarding a possible investment Grifols approves the payment of an interim dividend on account of 2018 Grifols presents AMBAR top-line results at the "Clinical Trials on Alzheimer's Disease" (CTAD) Response to recent published research Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives Grifols expands its plasma collection network by acquiring 24 Biotest centers in the United States Grifols closes the acquisition of Haema AG Information on the resolutions approved at the Annual General Meeting of Shareholders on May 25, 2018 Grifols reaches an agreement with Boya Bio-Pharmaceutical to open plasma collection centers in China Notice of Annual General Shareholders' Meeting 2018 Grifols has entered into an agreement with Aton GmbH for the purchase of 100% of the shares of German based pharmaceutical company Haema AG Appointment of new Chairperson of the Audit Committee Impact of the U.S. tax reform and other non-recurring items – Additional information (Spanish version) Impact of the U.S. tax reform and other non-recurring items – Additional information (Spanish version) Impact of the U.S. tax reform and other non-recurring items – Additional information Impact of the U.S. tax reform and other non-recurring items Grifols acquires a 51% in the U.S. technology firm MedKeeper for USD 98 million

2017

Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives Grifols inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components FDA approval of genetic test for alpha-1 deficiency and EMA approval of fibrin sealant Payment details of the interim dividend on account of 2017 earnings FDA approves a new Grifols product, fibrin sealant ("Fibrin Sealant") The Board of Directors approves an interim dividend on account of 2017 results FDA approves Grifols Prolastin®-C Liquid for the treatment of alpha-1 antitrypsin deficiency Grifols announces the acquisition of an additional 40% equity stake in Kiro Grifols Grifols acquires a 44% shareholding in GigaGen Manufacturing and supply agreement Information on the resolutions approved at the Annual General Meeting of Shareholders on May 26, 2017 Listing on the ISE of the Senior Unsecured Notes due 2025 and delisting of the Notes due 2022 Notice of Annual General Shareholders' Meeting 2017 Grifols has closed EUR 1.0 billion senior unsecured bond issue concluding its debt refinance process Communication to the Irish Stock Exchange Communication to the Irish Stock Exchange Grifols has concluded the refinancing process of part of its financial debt Grifols closes the acquisition of Hologic's share of NAT donor screening unit Grifols to acquire the 49% in Access Biologicals Grifols starts the refinancing process

2013

Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 17, 2013 Grifols communicates the acquisition of 21.30% of the biotechnological company TiGenix N.V. Notice of Extraordinary General Shareholders' Meeting December 2013 Grifols to acquire Novartis diagnostics business unit for US$1,675 million Grifols, S.A. informs the start of a clinical trial in phase I of the ABvac40 vaccine for patients with Alzheimer's disease Grifols informs of the closing of the subscription of the shares of Aradigm Corp Grifols informs that Moody's Investors Services has upgraded the company credit ratings Information on the resolutions approved at the Annual General Shareholders Meeting on May 24, 2013 Grifols signs an exclusive worldwide license agreement with Aradigm to develop and commercialize Pulmaquin™ Notice of Annual General Shareholders' Meeting 2013 New non-voting class B shares admitted to listing Registration with the Commercial Registry of the share capital increase and the issuance of new Class B non-voting shares Grifols purchases ADRs from Cerberus' Grifols announces the acquisition of 60% of the share capital of Progenika Biopharma S.A. New non-voting class B shares admitted to listing Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares

2011

New non-voting class B shares admitted to listing in Spain Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares Announcement of Grifols S.A Share Capital Increase Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 2, 2011 3Q results reporting date postponed Notice of Extraordinary General Shareholders' Meeting December 2011 Grifols announces the closing of the transaction to acquire 100% of the capital of the Australian-Swiss group, Lateral-Medion Execution of the agreement with Kedrion Closing of the acquisition of Talecris Biotherapeutics Grifols and Talecris announce that the FTC accepted for public comment the Consent Agreement Changes in the board of directors Registration of the "Nota sobre Acciones" (Securities Note) of the Class B non voting shares with the "CNMV" (National Securities Market Commission) Information on the resolutions approved at the Ordinary general shareholders meeting Grifols and Talecris Biotherapeutics announce the signing of a Consent Agreement with FTC Staff Notice of Annual General Shareholders Meeting 2011 Grifols and Talecris disclose the extension of the outside date under their merger agreement and the financing commitments New timing agreement with the FTC to provide advance notice of the consummation of the acquisition of Talecris Agreement with the FTC to extend the timing of the resolution for the acquisition of Talecris Information of the resolutions passed at the Extraordinary General Shareholders Meeting held January 25th 2011 Filing with the Securities Exchange Commission of the F-4 relating to the proposed acquisition of Talecris Grifols closes USD 1.1 billion bond issue (This release will not be distributed in the United States of America, Canada, Australia or Japan)

2010

Notice of Extraordinary General Meeting Grifols obtains EMA license to market its IVIG, Flebogamma® DIF, at 10% concentration Grifols signs term loan agreements related to Talecris acquisition for USD 3.4 billion Changes in the merger consideration of the Agreement and Plan of Merger as a consequence of the settlement of a class action Resolution by the " Comisión Nacional de la Competencia" Clarification on press releases published in certain media Shareholders' commitment to the proposed acquisition of Talecris Grifols expects to close for an amount of USD1.5B the first tranche of the syndicated Financing to acquire Talecris Grifols obtains FDA license in the US market for its IVIG Flebogamma® DIF 10% concentration Preliminary version of the F4 filed with the SEC in connection with the proposed acquisition of Talecris Grifols obtains its first crédit rating from Standard & Poor's and Moody's Final dividend 2009 Information on the resolutions passed at the Annual General Shareholders Meeting on June 21st Voting agreement - amendment Agreement and Plan of Merger among Grifols and Talecris Biotherapeutics Holdings Corp Acquisition Announcement of Talecris Biotherapeutics Holdings Corp Voting agreement Analyst and investors' presentation regarding acquisition of Talecris Biotherapeutics Holdings Corp Conference call details Notice of Annual General Meeting Resignation of Christian Purlow from the Board of Directors

2007

Appointment of Edgar D. Jannotta as member of the Appointments and Remuneration Committee (Spanish Version) Grifols to announce Capital Investment Plan for 400 million euro over the next five years EMEA authorization to distribute Flebogamma DIF® in Europe (Spanish Version) Announcement of transfer of shares (Spanish Version) Announcement on Grifols dividend payment (Spanish Version) Information on the resolutions passed by the General Shareholders Meeting held on June 20th, 2007 (Spanish Version) Annual General Meeting Announcement (Spanish Version) Grifols enters into an agreement for the management of four new plasma centers in the USA (Spanish Version) Grifols has entered into an agreement for the acquisition of Diesse. The closing of the transaction is subject to the outcome of the due diligence review, which the company expects will last until next June. (Spanish Version) Morgan Stanley & Co. International Ltd announces the completion of the placement (Spanish Version) Morgan Stanley & Co. International Ltd announces a private placement of 1.41% of Grifols S.A. share capital (accelerated bookbuilding) (Spanish Version) Extension of the Communication number 22.629 on the FDA approval for the indication of von Willebrand disease. (Spanish Version) The FDA approves the indication of von Willebrand disease for Alphanate (Spanish Version)